Andrea Hinton, MD

All Publications

• The Biology of Nails Hinton, A., Rana, J., Yost, J. McGraw Hill Professional. 2025 ; Taylor & Kelly Dermatology for Skin of Color, 3rd edition

  Abstract

  Chapter 17 (Accepted, publication expected in 2025.)

• Lime-Induced Phytophotodermatitis: A Rash That Requires Explicit Questioning. The journal of allergy and clinical immunology. In practice Jiang, S. Y., Wright, C. M., Hinton, A., Green, G., Moyer, A. R., Gerstbacher, D., Kushner, L. E., Wang, M. E., Schor, J. S., Trietsch, J., Chu, D., McGhee, S. 2024

  View details for DOI 10.1016/j.jaip.2024.02.035

  View details for PubMedID 38506786

• Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitors. Journal of the American Academy of Dermatology Thompson, L. L., Chang, M. S., Polyakov, N. J., Blum, A. E., Josephs, N., Krasnow, N. A., Yoon, J., Li, E. B., Molina, G. E., Said, J. T., Huang, K., Kuchroo, J. R., Hinton, A. N., Chen, S. T. 2022; 86 (4): 886-889

  View details for DOI 10.1016/j.jaad.2021.03.024

  View details for PubMedID 33722547

• Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. The British journal of dermatology Thompson, L. L., Li, E. B., Krasnow, N. A., Chang, M. S., Said, J. T., Molina, G. E., Polyakov, N. J., Yoon, J., Dee, E. C., Huang, K., Blum, A. E., Kuchroo, J. R., Hinton, A. N., Reynolds, K. L., Chen, S. T. 2021; 185 (3): 627-635

  Abstract

  Cutaneous immune-related adverse events (cirAEs) are a common side-effect of immune checkpoint inhibitors (ICIs). However, prior work examining these toxicities in detail has considered only the fraction of events evaluated by dermatologists. Associations between dermatology referral, cirAE treatment and survival outcomes remain underexplored across care settings.To comprehensively categorize cirAE patterns among all patients treated with immunotherapy at our institution, and to evaluate: (i) the effect of dermatology referral on cirAE treatment and (ii) the impact of cirAE treatment on survival.This was a retrospective cohort analysis of patients with cancer who initiated ICI therapy between 1 January 2016 and 8 March 2019 and developed one or more cirAEs, as screened for using International Classification of Diseases 10th revision codes and confirmed via manual chart review (n = 358). All relevant information documented prior to 31 March 2020 was included.CirAEs evaluated by dermatologists were significantly more likely to be treated than cirAEs that were not referred (odds ratio 6·08, P < 0·001). Patients who received any cirAE treatment had improved progression-free survival [hazard ratio (HR) 0·59, P = 0·001] and overall survival (HR 0·58, P = 0·007) compared with those who did not.CirAEs evaluated by dermatologists were significantly more likely to be treated than cirAEs that were not referred, and patients who received any treatment for a cirAE had improved survival outcomes.

  View details for DOI 10.1111/bjd.20074

  View details for PubMedID 33733456

• Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. JAMA dermatology Thompson, L. L., Krasnow, N. A., Chang, M. S., Yoon, J., Li, E. B., Polyakov, N. J., Molina, G. E., Said, J. T., Huang, K., Kuchroo, J. R., Hinton, A. N., Reynolds, K. L., Chen, S. T. 2021; 157 (5): 577-582

  Abstract

  Cutaneous immune-related adverse events (cirAEs) are some of the earliest toxic reactions to emerge following immune-checkpoint inhibitor (ICI) initiation. As an early indicator of robust inflammatory response, cirAEs may be associated with patterns of immune-mediated toxic effects, but associations between these events and noncutaneous immune-related adverse events (irAEs) remain underexplored.To characterize patterns of cirAEs and irAEs across care settings and examine associations between the features of first cirAE, overall irAE risk, and risk of specific irAE subtypes.A retrospective cohort study was conducted at a single academic medical center. The cohort included 358 patients with cancer who initiated anti-programmed death 1/ligand 1 and/or anticytotoxic-T-lymphocyte-4 ICI therapy between January 1, 2016, and March 8, 2019, and developed 1 or more cirAEs, identified using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes and confirmed via manual medical record review. All relevant information documented before March 31, 2020, was included.Anti-programmed death 1/ligand 1 and/or anticytotoxic-T-lymphocyte-4 therapy.Associations between specific cirAE morphologic classes and patterns of irAEs (occurrence, timeline, organ class, and specific toxic effects). Given the potential that shared underlying factors are associated with the risk of both noncutaneous and cutaneous toxic effects, the presence of observed positive associations between certain cirAE and irAE subtypes was hypothesized.Of the 358 patients, 213 were men (59.5%); median age was 65 years (interquartile range, 55-73 years). Nearly half of the patients (177 [49.4%]) with cirAE also developed a noncutaneous irAE. Most patients (128 [72.3%]) experienced their first cirAE before developing any irAE. Several cirAE morphologic classes were found to be associated with overall, organ-based, and specific irAEs. More specifically, mucositis was found to be associated with overall irAE risk (odds ratio [OR], 5.28; 95% CI, 1.11-24.26; P = .04), gastrointestinal irAEs (OR, 5.70; 95% CI, 1.11-29.40; P = .04), and the specific diagnosis of gastroenterocolitis (OR, 6.80; 95% CI, 1.24-37.39; P = .03). In addition, psoriasis was associated with an increased risk of endocrine irAEs (OR, 4.54; 95% CI, 1.21-17.04; P = .03).In this cohort study, these findings underscore the risk of multisystem toxic effects in patients experiencing cirAEs and highlight potential opportunities for dermatologists in the management of noncutaneous toxic effects.

  View details for DOI 10.1001/jamadermatol.2021.0326

  View details for PubMedID 33760001

  View details for PubMedCentralID PMC7992016

• Alcohol-Related Dermatitis: A Review. Dermatitis : contact, atopic, occupational, drug Hinton, A. N., Goldminz, A. M. 2020; 31 (3): 185-190

  Abstract

  : Wine, beer, liquor, and spirits are widely consumed in many cultures across the globe, and for some individuals, ingestion, cutaneous contact, or other exposure can lead to dermatologic findings. However, there currently exist no comprehensive reviews on alcohol-related dermatitis. Herein, we will provide an overview of alcohol-related dermatitis and contact urticaria, including the epidemiology and clinical manifestations, potential allergens found in alcoholic beverages, testing approaches, and strategies for allergen avoidance.

  View details for DOI 10.1097/DER.0000000000000579

  View details for PubMedID 32217881

• Feeling the Burn: Phototoxicity and Photoallergy. Dermatologic clinics Hinton, A. N., Goldminz, A. M. 2020; 38 (1): 165-175

  Abstract

  An interaction between light's radiation and certain exogenous and endogenous substances can lead to the development of photoallergic and/or phototoxic dermatoses. Clinically, reactions may range from acute and self-limited to chronic and recurrent. Delays in diagnosis are not uncommon due to complex clinical presentations, broad differentials, and limited number of specialists who perform phototesting. Therefore, a critical understanding of these dermatoses is essential for accurate diagnosis and appropriate management. The epidemiology, light sources, mechanisms, clinical presentations, evaluation protocols, common culprits, treatments, key challenges, and future directions related to photoallergy and phototoxicity are reviewed herein.

  View details for DOI 10.1016/j.det.2019.08.010

  View details for PubMedID 31753189